Bosentan vs Macitentan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: Endothelin receptor (ETA/ETB, dual) · full Pulmonary Arterial Hypertension pipeline
Bosentan · Tracleer
Marketed by Johnson & Johnson and partners
NCT00091715 · Phase 3 · completed
The study was randomized and quadruple-blinded, with a placebo control and 185 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
exercise capacity (Baseline to end of study); cardiac hemodynamics (Baseline to end of study): Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) (mixed)
Result source: NCT00091715
Macitentan · Opsumit
Marketed by Johnson & Johnson
NCT02932410 · Phase 3 · completed
The study randomized 148 children aged 2 years or older to open-label macitentan or standard care, but it was not blinded, and additional children younger than 2 years or enrolled in China received macitentan without randomization. The posted primary endpoints were pharmacokinetic blood concentrations rather than clinical outcomes, with no formal treatment comparison; clinical disease-progression results remain unreported.
Reported efficacy
Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier (met)
Result source: NCT00660179
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Bosentan: 7 of 7 rows · Macitentan: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bosentan Rows use multiple source trials | Macitentan Rows use multiple source trials |
|---|---|---|
| 6MWD - Change absolute change · m | 14.08 vs 17.42 placebo m @ 12wka,b,c,d NCT00323297 · Phase 4 · registry result, not featured evidence | 12.5 vs -9.4 placebo m @ 26wk10 mge,a,b,c,d NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 show 1 more dose7.4 vs -9.4 placebo m @ 26wk3 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 |
| Borg Dyspnea absolute change · score | -0.73 vs 0.16 placebo score @ 12wka,f,c,g NCT00323297 · Phase 4 · registry result, not featured evidence | -0.22 vs -0.29 placebo score @ 16wka,f,c,g NCT01743001 · Phase 3 · registry result, not featured evidence |
| WHO FC Worsening event count · % of participants No placebo or comparator arm Worsened WHO FC | 15.2% (n=33) @ 78wk*2mg/kg b.i.d.e,h,b,c,i NCT01338415 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted show 1 more dose9.7% (n=31) @ 78wk*2mg/kg t.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted | 1.1% (n=87) @ 26wk*10 mgh,b,c,i Worsened WHO FC NCT02310672 · Phase 4 · registry result, not featured evidence · converted to % from 1 Participants as posted |
| Dropout rate | 52.2%j NCT00303459 · Phase 4 · registry result, not featured evidence show 13 more results14% NCT00323297 · Phase 4 · registry result, not featured evidence 5.4% NCT00367770 · Phase 4 · registry result, not featured evidence 30.3%2mg/kg b.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence —2mg/kg t.i.d NCT01338415 · Phase 3 · registry result, not featured evidence 29%2mg/kg t.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence —2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence 0%2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence 0%2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00319020 · Phase 3 · registry result, not featured evidence 0% NCT01721564 · Phase na · registry result, not featured evidence | 0%China Single-arm Cohort (>=12 to <k NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 10 more results11.1%Macitentan (JNJ-67896062) (<2 Year NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 19.2%Macitentan (JNJ-67896062) (>=2 Yea NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Macitentan (JNJ67896062) (<2 Years NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 16.9%10 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 23.2%3 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 39.3%10 mg NCT00667823 · Phase 3 · monotherapy 17.2%10 mg NCT02310672 · Phase 4 · registry result, not featured evidence 0% NCT05167825 · Phase 3 · registry result, not featured evidence 2.6% NCT01743001 · Phase 3 · registry result, not featured evidence 15.2% NCT01841762 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —j NCT00303459 · Phase 4 · registry result, not featured evidence show 13 more results4% NCT00323297 · Phase 4 · registry result, not featured evidence 2.7% NCT00367770 · Phase 4 · registry result, not featured evidence 24.2%2mg/kg b.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence —2mg/kg t.i.d NCT01338415 · Phase 3 · registry result, not featured evidence 19.4%2mg/kg t.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence —2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00319020 · Phase 3 · registry result, not featured evidence — NCT01721564 · Phase na · registry result, not featured evidence | —China Single-arm Cohort (>=12 to <k NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 10 more results—Macitentan (JNJ-67896062) (<2 Year NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Macitentan (JNJ-67896062) (>=2 Yea NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Macitentan (JNJ67896062) (<2 Years NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 —10 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 —3 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 1.3%10 mg NCT00667823 · Phase 3 · monotherapy —10 mg NCT02310672 · Phase 4 · registry result, not featured evidence — NCT05167825 · Phase 3 · registry result, not featured evidence — NCT01743001 · Phase 3 · registry result, not featured evidence — NCT01841762 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 45.9%j NCT00303459 · Phase 4 · registry result, not featured evidence show 13 more results44% NCT00323297 · Phase 4 · registry result, not featured evidence 18.9% NCT00367770 · Phase 4 · registry result, not featured evidence 45.5%2mg/kg b.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence 41.9%2mg/kg t.i.d NCT01338415 · Phase 3 · registry result, not featured evidence —2mg/kg t.i.d. NCT01338415 · Phase 3 · registry result, not featured evidence 12.1%2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg b.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence 19.4%2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence —2 mg/kg t.i.d. NCT01223352 · Phase 3 · registry result, not featured evidence 5.6%400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 10.5%200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 50% NCT00319020 · Phase 3 · registry result, not featured evidence 0% NCT01721564 · Phase na · registry result, not featured evidence | 12.5%China Single-arm Cohort (>=12 to <k NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 10 more results—Macitentan (JNJ-67896062) (<2 Year NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 36.1%Macitentan (JNJ-67896062) (>=2 Yea NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 44.4%Macitentan (JNJ67896062) (<2 Years NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 45%10 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 52%3 mg NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 64.4%10 mg NCT00667823 · Phase 3 · monotherapy 17.2%10 mg NCT02310672 · Phase 4 · registry result, not featured evidence 28.6% NCT05167825 · Phase 3 · registry result, not featured evidence 6.1% NCT01743001 · Phase 3 · registry result, not featured evidence 17.3% NCT01841762 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | j oedema peripheral 18.9% (placebo 14.9%) headache 15.1% (placebo 13.8%) cough 13.8% (placebo 12.1%) NCT00303459 · Phase 4 · registry result, not featured evidence show 9 more resultsdiarrhoea 14% (placebo 9.4%) headache 14% (placebo 13.2%) oedema peripheral 14% (placebo 15.1%) NCT00323297 · Phase 4 · registry result, not featured evidence oedema peripheral 18.9% nasopharyngitis 13.5% chest pain 10.8% NCT00367770 · Phase 4 · registry result, not featured evidence 2mg/kg b.i.d. upper respiratory tract infection 27.3% nasopharyngitis 18.2% pyrexia 15.2% NCT01338415 · Phase 3 · registry result, not featured evidence 2mg/kg t.i.d upper respiratory tract infection 41.9% pyrexia 22.6% diarrhoea 19.4% NCT01338415 · Phase 3 · registry result, not featured evidence 2 mg/kg b.i.d. upper respiratory tract infection 18.2% nasopharyngitis 15.2% pyrexia 12.1% NCT01223352 · Phase 3 · registry result, not featured evidence 2 mg/kg t.i.d. upper respiratory tract infection 35.5% pyrexia 19.4% diarrhoea 12.9% NCT01223352 · Phase 3 · registry result, not featured evidence 400 mg/Day vomiting 22.2% anaemia 16.7% blood potassium decreased 16.7% NCT01392469 · Phase 3 · registry result, not featured evidence · combination 200 mg/Day diarrhoea 26.3% nausea 21.1% back pain 10.5% NCT01392469 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 19.4% abdominal pain 16.7% bronchitis 13.9% NCT00319020 · Phase 3 · registry result, not featured evidence | k cough 12.5% influenza 12.5% iron deficiency 12.5% NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 9 more resultsupper respiratory tract infection 30.6% headache 19.4% nasopharyngitis 19.4% NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 upper respiratory tract infection 44.4% covid-19 22.2% gastroenteritis 22.2% NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 10 mg oedema peripheral 18.2% (placebo 18.1%) upper respiratory tract infection 15.3% (placebo 12.9%) nasopharyngitis 14% (placebo 10.4%) NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 3 mg upper respiratory tract infection 19.2% (placebo 12.9%) oedema peripheral 16% (placebo 18.1%) nasopharyngitis 14.8% (placebo 10.4%) NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 10 mg upper respiratory tract infection 22% nasopharyngitis 19.1% oedema peripheral 19.1% NCT00667823 · Phase 3 · monotherapy 10 mg oedema peripheral 21.8% headache 20.7% dizziness 13.8% NCT02310672 · Phase 4 · registry result, not featured evidence nasopharyngitis 85.7% pyrexia 57.1% adenovirus infection 42.9% NCT05167825 · Phase 3 · registry result, not featured evidence headache 11.4% (placebo 4.5%) upper respiratory tract infection 9.6% (placebo 6.3%) bronchitis 5.3% (placebo 2.7%) NCT01743001 · Phase 3 · registry result, not featured evidence oedema peripheral 17.6% headache 12.7% dyspnoea 12% NCT01841762 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 26 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 12 weeks versus 16 weeks.
- hTrial phases differ: Phase 3 versus Phase 4.
- iAssessment timepoints differ: 78 weeks versus 26 weeks.
- jPopulation comparability has not been reviewed for these studies.
- kPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bosentan
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 44 further endpoints in the CSV export.
Macitentan
show 11 more results
show 11 more results
show 23 more results
show 1 more result
show 1 more result
show 2 more results
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bosentan's landscape · Macitentan's landscape